Pfizer CEO Albert Bourla has promised to reduce costs by one Billion Dollars annually by 2025 following the completion of the Seagen purchase. So Bourla is not trusting only increased profits from Seagen products to make those debt payments. It's down to those synergies they always promise. But investors are rightly skeptical since Merck walked away from a Seagen purchase last year because the price was too high.